Aims Previous surveys have shown that patients with type 2 diabetes and coronary heart disease (CHD) are infrequently treated to risk factor targets in current guidelines. Our aim was to examine risk factor management and achievement of current targets in 2005 among Swedish type 2 diabetic patients with CHD. 
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Introduction
The risk of coronary heart disease (CHD) is substantially increased in patients with type 2 diabetes [1, 2] . In addition, the mortality one year after CHD is higher in patients with as compared to without diabetes [3] . Glycaemic control can reduce the risk of microvascular endpoints [4] , and MI if metformin is used [5] . The importance of treatment with antihypertensive drugs, lipid-lowering drugs and antiplatelet drugs for primary prevention of cardiovascular disease has also been documented [6] [7] [8] . Recently the benefit of statin use in patients with diabetes was high-lighted in a meta-analysis by the Cholesterol Treatment Trialists´ (CTT) Collaborators [9] .
The Swedish National Diabetes Register (NDR) was initiated in 1996 as a tool for quality assurance in diabetes care, with reports of patient data from hospital outpatient clinics and primary health care (PHC) centres nationwide. A more detailed description of the NDR and Swedish diabetes care has been published previously [10] [11] [12] [13] [14] [15] . It offers a unique possibility to survey the treatment and risk factor control in patients with diabetes based on data from everyday clinical practice.
The aim of this study was to examine risk factor management in 2005 among type 2 diabetic patients with first incident of CHD, by a comparison between patients from the NDR who had CHD 1-2 years previously or CHD 3-7 years previously, and by a comparison between sexes.
Patients and methods
Reporting to the NDR is based on information collected during patient visits at hospital outpatient clinics and PHC centres all over Sweden. This is carried out by trained nurses or physicians via the Internet (www.ndr.nu), by transferral of data from clinical records databases or by use of a printed form. All information is subsequently stored in a central database, and participating centres receive an annual report with local results compared with national for feed-back. Ninety-five percent of all hospital diabetes outpatient clinics and 75 4 percent of all PHC centres in Sweden participated in the NDR during 2005. The mean numbers of reported patients were 402 and 144 per participating unit, respectively. Reporting to the NDR is not mandatory, but hospital outpatient clinics and PHC centres nationwide are encouraged to participate. All patients gave informed consent before agreeing to be included.
The Regional Ethics Committee at the University of Gothenburg approved the study. Reports concerning the national data have been previously published by the Working Group of the NDR, describing trends in risk factor control, also including a more detailed description of the Swedish health care system for patients with diabetes [10] [11] [12] [13] [14] [15] .
This study concerns 1719 female and male type 2 diabetic patients (age 18-79 years) with first incident of nonfatal CHD 1-2 years before follow-up in 2005, and 3843 female and male type 2 diabetic patients (age 18-79 years) with first incident of CHD 3-7 years before follow-up in 2005, and with data available in the NDR for an analysis of risk factors in 2005.
All patients had diabetes when the CHD event occurred. The first period was chosen to allow for a comparison with the EUROASPIRE study, and the second period was added to allow for a comparison with patients who had a CHD event during another five-year period before the first period. About 80% of the patients in this study were treated at PHC centres. The definition of type 2 diabetes applied was treatment with diet only, or treatment with oral hypoglycaemic agents, or with insulin only or insulin combined with oral agents and age 40 years or more when diabetes was detected. HbA1c, and elaborated in a large observational study obtained from type 2 diabetic patients on routine treatment in Sweden with age up to 70 years, as previously described (19) . 
Definition of coronary heart disease events

Statistical methods
Results are presented as mean values ± one standard deviation (SD) or frequencies in Tables 1-3 . Significance levels were adjusted for differences in age and sex by multivariate and logistic regression. Multivariate regression was used in Table 4 
Results
Patients with CHD 1-2 years previously
Mean age was 67+8 years, 68% were males, and mean diabetes duration was 9+8 years at follow-up in 2005 ( Table 1 ). The proportion of treatment with oral hypoglycaemic agents was 59%, and as many as 44% had insulin. The current HbA 1c target <7% was achieved by 54%, while as many as 81% reached HbA1c <8%. Achievement of blood lipid level targets are given in Table 2 : total cholesterol <4.5 mmol/L by 59%, LDL cholesterol <2.5 mmol/L by 66%, non-HDL cholesterol <3.4 mmol/l by 68%, triglycerides <1.7 mmol/L by 52%, and HDL cholesterol >1.0 mmol/L (males) or 1.3 mmol/L (females) by 59%. This was accompanied by a high proportion of patients using lipid-lowering drugs (mainly statins), 85%. was high, 43% . Few patients, 10%, reached the current target for waist circumference, and only 31% a less stringent target. Furthermore, the proportion of smokers was 13% in all patients, and as many as 19% in a subgroup of patients with age less than 65 years.
Physical exercise was performed regularly three times per week or more in around half of the patients.
The mean estimated 5-year risk of CVD was 18%, with 17% of all below risk <10% and 65% below risk <20%.
Patients with CHD 3-7 years previously
Comparing patients with CHD 3-7 years before follow-up to those with CHD 1-2 years before follow-up (Table 1) , no significant differences were seen regarding hypoglycaemic treatment or achievement of targets for HbA1c, BP and life style characteristics. Concerning targets for blood lipids, significantly less patients achieved targets for total cholesterol, non-HDL cholesterol, triglycerides and total /HDL cholesterol among patients with CHD 3-7 years previously. The mean 5-year risk of CVD was slightly higher, with less patients below risk <10% and <20% (p <0.05-0.01).
Gender differences
Comparing women and men in 2005 with CHD 1-2 years previously (Table 3) , women had higher mean HbA1c, BMI, blood lipids, and less regular exercise than men, while women had lower mean diastolic BP, waist and microalbuminuria. No significant differences were seen 8 regarding hypoglycaemic treatment, mean systolic BP, smoking, use of antihypertensive drugs, lipid-lowering drugs or aspirin. The mean 5-year risk of CVD was higher in men than women, 19 versus 15%, and less men were below risk <10% and <20. The same picture was seen when comparing women and men with CHD 3-7 years previously.
Years passed since CHD event versus risk factor control
Multiple regression analysis was used to investigate the association between time (years) from first incident CHD to follow-up as dependent variable and risk factor status in 2005 as independent variables, see Table 4 . Median (range) years was 4 (1-7). It was found that the number of years from CHD to follow-up was significantly associated with levels of total cholesterol, smoking and BMI (positively) and HDL cholesterol (negatively). Thus, levels of these risk factors deteriorated with longer time from CHD to follow-up. Levels of HbA 1c and BP, however, did not deteriorate with time.
Discussion
The implementation of evidence-based therapies [17, 18] and optimised risk factor control is especially important in patients with the combination of diabetes and CHD, as potential health benefits are proportional to risk factor levels achievement and the proportion of patients treated with drugs such as statins [9] . This study demonstrated that the current treatment targets for blood lipids were achieved by around 60% of the patients with combination of type 2 diabetes and CHD in 2005, while the current targets for blood pressure control and glycaemic control (HbA1c)
were reached by about 40-50% of the subjects. A high prevalence of adverse lifestyle characteristics was found, mean BMI and waist circumference were high, obesity was present in more than 40%, and a high waist circumference above target level in 70%. As many as around 20% of patients aged <65 years continued to smoke in 2005, and only around 50% exercised regularly three times per week or more.
A high proportion of use of lipid-lowering drugs (almost exclusively statins) was found in patients with CHD 1-2 years previously, 85%. This was accompanied by the achievement of current targets for total cholesterol, LDL cholesterol and non-HDL cholesterol in as many as 60-68% of these patients, Current triglycerides and HDL-cholesterol targets were attained by more than 50%, although statins do not have their main effect on these blood lipids variables. Both triglycerides and HDL-cholesterol have been verified as risk factors for cardiovascular disease, and are also indicators of dyslipidaemia associated with insulin resistance [20, 21] . Concerning patients with CHD 3-7 years previously, targets for total, non-HDL, LDL cholesterol and triglycerides, were somewhat and significantly less frequently achieved, compared to patients with CHD 1-2 years previously. Multivariate regression showed that total cholesterol levels were higher and HDL cholesterol levels lower with longer time from CHD event to follow-up.
As many as four-fifths of patients with CHD reached a less stringent HbA 1c target <8.0% in patients with CHD 1-2 years previously. However, only half of the subjects reached the current HbA 1c target <7.0%. No significant differences were seen regarding these targets between patients with CHD 1-2 or 3-7 years previously. Strongly intensified lifestyle measures and possible use of weight-reducing therapies seem necessary in order to obtain a higher achievement of the current HbA 1c target, also with regard to the high proportion of obesity. Regular exercise 30 min twice per week has been shown to reduce cardiovascular risk by 30% in patients with hypertension [22] . This necessity was also underlined by the finding that almost one-fifth had microalbuminuria, a marker of greatly increased cardiovascular morbidity and mortality in patients with type 2 diabetes [13, 23] .
Mean estimated 5-year risk in all patients, 19%, was higher than in ~11.000 Swedish type 2 diabetic patients with no previous CVD, 12% (19) , based on clinical parameters and HbA1c, although not taking into account the increase in risk due to previous CHD.
Some previous surveys have analysed risk factor management in diabetic patients with coronary artery disease [24] [25] [26] [27] . The EUROASPIRE II Study was carried out in 1,086 male and female type 2 diabetic patients (mean age 63 years) with CHD 1-2 years before followup in 1999-2000 [25] . Considerably more patients with CHD 1-2 years before 2005 in this study reached current targets for total cholesterol and LDL-cholesterol, 60% and 66%, than in EUROASPIRE II, 29% and 25%. Accordingly, 84% used lipid-lowering drugs in the Swedish study, while only 62% in EUROASPIRE II. However, the achievement of BP <130/80 mmHg was similar in both studies, 24% versus 23%, in spite of a high use of antihypertensive drugs in both studies, 94% versus 92%, respectively. Furthermore, many patients were still smoking in both studies, 12% versus 17%. The recent Euro Heart Survey on Diabetes and the Heart examined 1524 diabetic patients with coronary heart disease from 25 countries in 2003, and found that only 30% achieved the BP target <140/90 mmHg [26] .
Lipid-lowering drugs were given to 66%, while only 45% reached total cholesterol <5 mmol/l and LDL cholesterol <3 mmol/l.
Comparatively in this study in 2005, 84% had lipid-lowering drugs, and around 80% achieved these two lipid targets (data not given in Results).
In Swedish patients with diabetes and myocardial infarction, the national RIKS-HIA register-based study has demonstrated a clear decrease in one-year post-MI total mortality from 29.7% to 19.7% during the period 1995-2002, although still higher than in patients without diabetes, 16.6% to 12.1% [28, 29] . The relative one-year mortality risk in diabetic patients, compared with non-diabetic patients, encouragingly decreased significantly from 
Limitations of the study
The coverage rate of the Swedish diabetic population in the NDR is still not optimal, but almost 40% of all type 2 diabetic patients in Sweden were registered in 2005. A possible bias that centers with particular interest in diabetes care might report more patients in the early development of a national register was not probable in this study, as the NDR was started as early as in 1996. Patients excluded due to missing data regarding the HbA1c and BP variables were 10% of all available patients, with similar mean age and male rate (67+8 years and 65%). Concerning the number of participants with CHD 1-2 years previously, it was larger in this study from one country than comparable participants in EUROASPIRE I and II from 15 countries, 1086 and 641, respectively (25) . We believe that data regarding onset age of diabetes, continuous risk factor variables and use of drugs were reliable in this study.
Smoking might be somewhat biased due to under-reporting by patients or examiners. We also believe data concerning end-point events to be reliable as all events were diagnosed during treatment at hospitals reporting to the national Mortality Register and the Hospital Discharge Register, and CHD defined by combining data from these registers is an efficient validated alternative to revised hospital discharge notes and death certificates [30] .
The strength of this study was supported by the fact that the numbers of patients and events were relatively high, and that patients in the NDR were collected from the general Swedish diabetes population at PHC centres and hospital diabetes clinics nationwide. Similar trends of improved control influencing prognosis has recently also been reported from another related Swedish register study, RIKS-HIA [29] . Table 1 , and were less than all included patients in Table 2 regarding TG (91%), HDL-C, non-HDL-C, TC/HDL-C (89%), LDL-C and LDL/HDL-C (83%). 
